 |
|
Intravenous Etidronate in the Management of Malignant Hypercalcemia
Elisabeth Ryzen, MD;
Raymond R. Martodam, PhD;
Mark Troxell, MD;
Al Benson, MD;
Alexander Paterson, MD;
Kirk Shepard, MD;
Richard Hicks
Arch Intern Med. 1985;145(3):449-452.
Abstract
• The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2,3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3±2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non—small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.
(Arch Intern Med 1985;145:449-452)
Author Affiliations
From the Orthopedic Hospital, Los Angeles (Dr Ryzen); Department of Oncology, Brooke Army Medical Center, San Antonio, Tex (Dr Troxell); Department of Human Oncology, University of Wisconsin, Madison (Dr Benson); Cross Cancer Institute, Edmonton, Alberta (Dr Paterson); Division of Hematology/Oncology, University of Chicago Hospital and Clinics (Dr Shepard); and Proctor & Gamble Co, Cincinnati (Dr Martodam and Mr Hicks).
Footnotes
Accepted for publication July 8, 1984.
Reprint requests to Proctor & Gamble Co, PO Box 39175, Cincinnati, OH 45247 (Dr Martodam).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Role of Bisphosphonates in Breast Cancer
Theriault
J Natl Compr Canc Netw 2003;1:232-241.
ABSTRACT
Malignant Hypercalcemia: The Choice of Therapy
List
Arch Intern Med 1991;151:437-438.
ABSTRACT
Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study
Singer et al.
Arch Intern Med 1991;151:471-476.
ABSTRACT
Effects of a New Aminodiphosphonate (Aminohydroxybutylidene Diphosphonate) in Patients With Osteolytic Lesions From Metastases and Myelomatosis: Comparison With Dichloromethylene Diphosphonate
Attardo-Parrinello et al.
Arch Intern Med 1987;147:1629-1633.
ABSTRACT
Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia
Schiller et al.
Arch Intern Med 1987;147:963-966.
ABSTRACT
Treatment of Cancer-Associated Hypercalcemia With Cisplatin
Lad et al.
Arch Intern Med 1987;147:329-332.
ABSTRACT
|
